Last reviewed · How we verify

XELOX intensive treatment group

Zhejiang Cancer Hospital · Phase 3 active Small molecule

XELOX intensive treatment group is a Platinum-based chemotherapy Small molecule drug developed by Zhejiang Cancer Hospital. It is currently in Phase 3 development for Colorectal cancer, Advanced colorectal cancer.

Oxaliplatin works by damaging the DNA of cancer cells, preventing them from reproducing.

Oxaliplatin works by damaging the DNA of cancer cells, preventing them from reproducing. Used for Colorectal cancer, Advanced colorectal cancer.

At a glance

Generic nameXELOX intensive treatment group
SponsorZhejiang Cancer Hospital
Drug classPlatinum-based chemotherapy
TargetDNA
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Oxaliplatin is a platinum-based chemotherapy drug that forms platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death. This mechanism is specific to rapidly dividing cells, such as cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about XELOX intensive treatment group

What is XELOX intensive treatment group?

XELOX intensive treatment group is a Platinum-based chemotherapy drug developed by Zhejiang Cancer Hospital, indicated for Colorectal cancer, Advanced colorectal cancer.

How does XELOX intensive treatment group work?

Oxaliplatin works by damaging the DNA of cancer cells, preventing them from reproducing.

What is XELOX intensive treatment group used for?

XELOX intensive treatment group is indicated for Colorectal cancer, Advanced colorectal cancer.

Who makes XELOX intensive treatment group?

XELOX intensive treatment group is developed by Zhejiang Cancer Hospital (see full Zhejiang Cancer Hospital pipeline at /company/zhejiang-cancer-hospital).

What drug class is XELOX intensive treatment group in?

XELOX intensive treatment group belongs to the Platinum-based chemotherapy class. See all Platinum-based chemotherapy drugs at /class/platinum-based-chemotherapy.

What development phase is XELOX intensive treatment group in?

XELOX intensive treatment group is in Phase 3.

What are the side effects of XELOX intensive treatment group?

Common side effects of XELOX intensive treatment group include Neurotoxicity, Myelosuppression, Diarrhea, Fatigue, Nausea and vomiting.

What does XELOX intensive treatment group target?

XELOX intensive treatment group targets DNA and is a Platinum-based chemotherapy.

Related